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ABSTRACT
The recent development of screening strategies
based on the generation and display of large
libraries of antibody fragments has allowed consid-
erable advances for the in vitro isolation of
monoclonal antibodies (mAbs). We previously de-
veloped a technology referred to as the ‘ADLib
(Autonomously Diversifying Library) system’, which
allows the rapid screening and isolation in vitro of
antigen-specific monoclonal antibodies (mAbs)
from libraries of immunoglobulin M (IgM) displayed
by the chicken B-cell line DT40. Here, we report a
novel application of the ADLib system to the pro-
duction of chimeric human mAbs. We have
designed gene knock-in constructs to generate
DT40 strains that coexpress chimeric human IgG
and chicken IgM via B-cell-specific RNA alternative
splicing. We demonstrate that the application of the
ADLib system to these strains allows the one-step
selection of antigen-specific human chimeric IgG. In
addition, the production of chimeric IgG can be
selectively increased when we modulate RNA pro-
cessing by overexpressing the polyadenylation
factor CstF-64. This method provides a new way to
efficiently design mAbs suitable for a wide range of
purposes including antibody therapy.
INTRODUCTION
The use of monoclonal antibodies (mAbs) has raised con-
siderable interest in recent years, notably for diagnostic
and therapeutic applications. The development of the
hybridoma technology (1) has allowed the extensive selec-
tion and production of mAbs speciﬁcally binding to target
antigens of interest, including several mAbs approved for
clinical use against human diseases such as cancer (2).
Still, conventional technologies based on animal immun-
ization to isolate new mAbs remain time-consuming, and
exclude the generation of mAbs against poorly immuno-
genic antigens such as auto-antigens and small
compounds.
To overcome these issues, various successful in vitro
screening systems of mAb fragment libraries have
emerged from molecular display technologies such as
phage display (3,4). Recently, we have developed a new
method for the rapid generation of mAbs using the
chicken B-cell-derived cell line DT40 (5,6). By enhancing
gene conversion (5,7), which is the main diversiﬁcation
process of the immunoglobulin (Ig) variable region in
chicken B cells (8,9), we obtained naturally expanding
libraries of mAbs displayed at the cell surface as
membrane-bound IgM. DT40 clones expressing
antigen-speciﬁc mAbs can then be isolated using
magnetic beads conjugated to any target antigen of
interest. This technology, named the ADLib system
(Autonomously Diversifying Library system) (5,6), has
the advantage of allowing the acquisition of whole IgM
molecules in a rapid and convenient manner. Moreover,
given the ease of genetic manipulation and culture of
DT40 cells (10), the selected clones can be readily
expanded and manipulated to accommodate the needs
for a scaled-up production or an improved immuno-
reactivity, including, for instance, the development of
in vitro afﬁnity maturation systems based on the genetic
enhancement of Ig hypermutation (11,12).
The ADLib system has proved to be an effective
method for the de novo acquisition of antigen-speciﬁc
mAbs of interest (5,6). However, one limitation was that
DT40 cells can produce only chicken IgM, in either its
membrane-bound or secreted form. Conversion to other
Ig isoforms, notably IgG, is often desirable for practical
use, especially for applications involving the recognition
of the Fc region. The development of in vivo assays and of
medical applications also requires the immunogenicity of
the mAb itself to be reduced as much as possible, which is
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versions of the selected mAb. In this report, we present
a novel approach for the direct generation of chimeric
human IgG in DT40 cell display libraries. By knock-in
of the human IgG constant region into the chicken IgM
heavy-chain locus, we designed DT40 derivatives that
express by alternative splicing both chicken IgM and
chimeric IgG sharing the same antigen-binding domain.
These strains can generate a library to screen for
antigen-speciﬁc mAbs by direct application of the
ADLib system, thus allowing the simultaneous isolation
of speciﬁc chimeric IgG of interest. In addition, we show
that the production of chimeric IgG can be selectively
increased over chicken IgM by modulating the efﬁciency
of RNA processing.
MATERIALS AND METHODS
Cell culture conditions
DT40 cells were cultured as previously described (5,7) in
IMDM (Invitrogen) supplemented with 10% fetal bovine
serum (FBS, SAFC Biosciences), 1% chicken serum
(Invitrogen), 50U/ml penicillin–50mg/ml streptomycin
(Invitrogen), 55mM 2-mercaptoethanol (Invitrogen), at
39.5 Ci n5 %C O 2 incubator. Media were changed regu-
larly every 1 or 2 days to maintain the cell density at
2 10
5 to 1.5 10
6cells/ml. TSA (Wako) was added in
the medium at each passage at 2.5ng/ml when indicated.
For puriﬁcation of chimeric IgG, cultures were transferred
the preceding day into a medium containing 10%
Ultra-Low IgG FBS (Invitrogen) instead of usual FBS
and no chicken serum to reduce contamination with
serum IgG.
Plasmid constructs
For the chimeric ch/hu-IgHG1 construct, we ﬁrst
ampliﬁed the full-length human IgHG1 constant region
(about 3kb comprising the exons CH1, H (hinge), CH2,
CH3 and the downstream polyadenylation signal) and
parts of the chicken IgHM constant region from human
genomic DNA using the expand long range PCR system
(Roche). Primer sequences are provided in Supplementary
Data S1. The fragments were cloned into the
pCR2.1TOPO vector with the TOPO TA cloning kit
(Invitrogen). As the direct ampliﬁcation of a large region
of chicken IgHM proved to be difﬁcult, we ﬁrst cloned
two overlapping fragments, from exon CH1t oC H2 then
from CH2t oC H3, and we ligated them at the PmlI restric-
tion site in exon CH2 using the DNA Ligation Kit Ver.2.1
(Takara) to reconstitute the entire region from CH1t o
CH3(  9kb). The DNA sequences of the cloned IgHG1
and IgHM regions were analyzed with an ABI3730xl se-
quencer (Applied Biosystems). We next inserted a
Blasticidin S resistance (bsr) marker cassette under
control of a b-actin promoter at the EcoRV site down-
stream of human IgHG1. We then extracted the MluI–
XhoI fragment comprising the IgHG1 exons H, CH2,
CH3 and the bsr marker. This fragment was inserted by
blunt ligation at the region digested by BseRI, in the
intronic region between exons CH1 and CH2 of chicken
IgHM, to make the ﬁnal ch/hu-IgHG1 plasmid.
For the CstF-64 overexpression construct, we extracted
total RNA from wild-type DT40 cells with Trizol reagent
(Invitrogen) and we ampliﬁed the CstF-64 cDNA ﬂanked
by the ClaI and NheI restriction enzyme sites (primers
provided in Supplementary Data S1) by reverse
transcription-polymerase chain reaction (RT-PCR)
(Superscript III One-step RT-PCR, Invitrogen). After
sequence veriﬁcation and digestion with ClaI and NheI,
we inserted the cDNA fragment in pIEn-NT, a vector
derived from pIRES-neo (Clontech) in which the CMV
expression promoter has been replaced by the CAGGS
promoter [containing the CMV enhancer and a chicken
b-actin promoter (13)].
Transformation of DT40 cells and constructs veriﬁcation
Transformation was performed following a standard
protocol. For the chimeric ch/hu-IgHG1 construct, 50mg
of the corresponding plasmid were linearized with NcoI to
transfect 1 10
7 wild-type DT40 cells by electroporation
(Bio-Rad Gene Pulser, 0.4cm gap, 550V, 25mFD). After
24h of incubation at 37 Ci n5 %C O 2 incubator, single
colonies of stable clones were selected in 96-well plates
with a medium containing 25mg/ml Blasticidin S. The
positive ch/hu-IgHG1 transformant strain used in this
study was named CX13. For the CstF-64 overexpression
construct, 50mg of plasmid were linearized with PvuI to
transfect 1 10
7 cells of the CX13 chimera strain and
stable clones were selected in medium containing
2mg/ml Geneticin (Invitrogen).
The expression of ch/hu-IgHG1 messenger RNA
(mRNA) was conﬁrmed by RT-PCR (Superscript III
One-Step RT-PCR, Invitrogen) after isolation of total
RNA using Trizol reagent (Invitrogen). Correct integra-
tion of the constructs was conﬁrmed by PCR analysis
(primers provided in Supplementary Data S1) using the
KOD FX enzyme (Toyobo) after isolation of genomic
DNA using the Illustra GenomicPrep Mini Spin Kit
(GE Healthcare). We also conﬁrmed by sequence
analysis the full sequence of the chimeric ch/hu-IgHG1
cDNA, from the chicken IgHM V-region to the human
IgHG1 constant region stop codon (sequence available
upon request).
Flow cytometry
1 10
6 cells were harvested and washed in staining buffer
[phosphate-buffered saline (PBS), 0.5% bovine serum
albumin (BSA, Sigma), 2mM EDTA], labeled for
surface IgM with 4mg/ml ﬂuorescein isothiocyanate
(FITC)-conjugated goat anti-chicken IgM antibody
(Bethyl), then with 5mg/ml propidium iodide (Sigma) to
gate out dead cells. The percentage of surface
IgM-positive cells (IgM
+) was determined by measuring
the FITC ﬂuorescence intensity with the Cytomics
FC500 ﬂow cytometer (Beckman Coulter).
Protein immunoblotting
Two to ﬁve microliters of WCE or serum supernatant
samples were diluted 1:1 in 2x Laemmli loading buffer
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2-mercaptoethanol, 20% glycerol, 0.004 % bromophenol
blue, 0.125 M Tris–HCl pH 6.8], denatured 5min at 95 C,
separated by SDS-polyacrylamide gel electrophoresis
(PAGE) on 10% acrylamide gels in a XCell SureLock
Mini-Cell (Invitrogen) and transferred onto nitrocellulose
membranes (Hybond-ECL, GE-Healthcare). The blots
were blocked in PBST (1x PBS, 0.05% Tween) with 5%
skim milk, incubated with the appropriate primary
antibody [1:10000 HFP-conjugated anti-human IgG-Fc
(Bethyl), HFP-conjugated anti-chicken IgM (Bethyl) or
1:5000 anti-FLAG antibody (Sigma)] diluted in PBST
with 1% skim milk for 1h at room temperature, then
with a secondary antibody if necessary [1:10000
HFP-conjugated anti-mouse IgG (sigma) for the
anti-FLAG immunoblotting]. Signals were detected by
exposure on Hyperﬁlm (GE Healthcare) using the ECL
western blotting reagents (GE Healthcare). Preparation
of deglycosylated proteins was performed by removal of
N-glycans using the enzyme PNGase F (New England
Biolabs) according to the protocol of the manufacturer,
with 2h incubation at 37 C for denatured proteins, or
overnight to 24h incubation for native proteins. Whole
human IgG1 Kappa (Sigma), diluted at 1mg/ml in PBS
or in the same culture medium as the samples, was used
as positive control for the detection of human IgG.
Puriﬁcation and concentration of chimeric IgG
Chimeric IgG expressing clones were cultured for 24h in
30ml medium with 10% Ultra-Low IgG FBS
(Gibco-Invitrogen) to a density of 2 10
6 cells/ml. After
centrifugation for 10min at 190g, the culture supernatant
was ﬁltered through a 22-mm ﬁlter membrane and puriﬁed
with a protein G afﬁnity chromatography column (Mab
Trap Kit, GE Healthcare) according to the protocol of the
manufacturer. Puriﬁed immunoglobulins were ﬁnally
eluted in 3ml buffer, thus resulting in an  10-fold
concentration.
Generation of diversiﬁed cell cultures for the ADLib
system
The selected chimeric CX13 cells were passaged every day
for 4 weeks in 12ml medium+2.5ng/ml TSA, then 2
weeks in 50ml medium+2.5ng/ml TSA. Analysis of
sequence diversiﬁcation at the IgL and IgH V-regions
were essentially performed as described (5,7). Genomic
DNA was extracted from 1 10
6 cells using the Illustra
GenomicPrep Mini Spin Kit (GE Healthcare) and 1:200 of
each sample (corresponding to 5000 cells) was used as
template for PCR ampliﬁcation of the V-regions
(primers in Supplementary Data S1). After puriﬁcation
of the PCR products and cloning into the pCR2.1
TOPO vector (Invitrogen), 15 clones for IgL and 24
clones for IgH were sequenced using the M13 universal
forward or reverse primers with an ABI 3730xl sequencer
(Applied Biosystems). Sequences were aligned to the
parental clone before expansion and to published
V pseudogene sequences (8,9) to determine the frequency
of sequence alterations due to gene conversion or point
mutation events.
Selection of antibodies with the ADLib system
The selection of monoclonal antibodies was performed as
described (5,6). Brieﬂy, we ﬁrst conjugated the target
antigen (apoferritin, Sigma) to M280 tosyl-activated
magnetic beads (Dynal) according to a standard
protocol (6). Then 5ml of antigen-coated beads (about
1.25 10
8 beads) were put into contact with the cells
from a 50ml ADLib culture (about 1 10
8 cells). After
several washing steps, the beads – along with the cells
bound to the target antigen, if any – were distributed
into a 96-well plate with fresh medium and incubated at
39.5 C, 5% CO2 for 1 week. Culture supernatants from
the wells containing growing colonies of antigen-binding
cells were analyzed by enzyme-linked immunosorbent
assay (ELISA) to screen for antigen-speciﬁc antibodies
secreted into the medium.
ELISA
ELISA experiments were performed as described (6).
Brieﬂy, the wells of a U-bottom maxisorp immunoplate
(Nunc) were incubated overnight at 4 C with the antigen
of interest diluted at 3mg/ml in PBS. After blocking with a
solution of 1% BSA in PBS for 30min and washing with
PBST (1  phosphate saline buffer, 0.05% Tween), 100ml
of culture supernatants were added to each well and
incubated for 1h at room temperature. After washing
ﬁve times with PBST, 100ml of secondary antibody
[1:10000 HRP-conjugated anti-chicken antibody or
1:2000 HRP-conjugated anti-human antibody (Bethyl)]
was added for 1h at room temperature. After washing
ﬁve times with PBST, immunoreactivity was revealed by
addition of 100ml 3,30,5,50-tetramethylbenzidine (TMB)
(Dako Cytomation) for 3min for anti-chicken antibody
and 5min for anti-human antibody. The reaction was
stopped with 100ml 1N sulfuric acid and the optical
density at 450nm was measured with a microplate
reader (Bio-Rad)
Quantitative ELISA
For sandwich ELISA, the wells of a U-bottom maxisorp
immunoplate (Nunc) were incubated for 1h at room tem-
perature with 100ml of anti-human IgG-Fc or anti-chicken
IgM antibody (Bethyl) diluted at 10mg/ml in PBS. After
blocking with a solution of 1% BSA in PBS for 30min
and washing with PBST, 100ml of a serial dilutions of
culture supernatant were added for 1h at room tempera-
ture, washed, then 100ml of 1:10000 HRP-conjugated
anti-human IgG-Fc or anti-chicken IgM (Bethyl) were
added for 1h at room temperature. After washing,
immunoreactivity was revealed by addition of 100ml
TMB (Dako Cytomation) for 3min, the reaction
stopped with 100ml 1N sulfuric acid, and the optical
density at 450nm was measured with a microplate
reader (Bio-Rad). A standard curve was generated from
the O.D. measurements of a control human IgG1 Kappa
or (Sigma) chicken IgM (Invitrogen) serially diluted in
culture medium from a starting concentration of
1mg/ml. Then the concentrations of chimeric IgG or of
chicken IgM in each sample were estimated from the
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range allowing linear regression (usually between
O.D.=0.6 and 1.2).
Competition ELISA
Comparison of mAb binding afﬁnities by competition
ELISA has been performed as previously described (14),
with some modiﬁcations. The selected samples of culture
supernatants were ﬁrst serially diluted in fresh culture
medium and titrated by anti-apoferritin ELISA as above
to determine the dilution required to obtain a maximal
signal of O.D.=0.7. The samples were then diluted
accordingly and incubated overnight at room temperature
with serial dilutions of apoferritin with concentrations
ranging from to 0.05 to 500nM. The mixed solutions
were then analyzed by anti-apoferritin ELISA to deter-
mine the concentration of antigen, which inhibits 50%
of the maximal binding by free antibodies (IC50)
by plotting the percentage of the maximal reactivity
signal as function of the concentration of competitor
antigen.
RESULTS
Construction and characterization of DT40 clones
expressing chicken/human chimeric IgG
The DT40 B-cell line constitutively produces membrane-
bound and secreted-form chicken IgM. We engineered
DT40 cells by targeted integration, so that they would
express chicken/human chimeric IgG, in which the Fc
domain of the IgM heavy-chain constant region has
been replaced by its human IgG1 counterpart (Figure 1).
To make the targeting vector, we ﬁrst cloned a human
genomic region including the last three exons (hinge H,
CH2, CH3) of the Ig gamma-1 heavy-chain constant region
(human IgHG1). As the ﬁrst exon CH1 is known to be
essential for correct assembly and secretion of chicken
light-heavy Ig chains (15), we decided to keep the
chicken IgM sequence for CH1 in this experiment. We
inserted the human IgHG1 fragment into the intronic se-
quences between exons CH1 and CH2 of the chicken Ig mu
heavy-chain constant region (chicken IgHM). After RNA
splicing, this construct is expected to transcribe mRNA
with chicken CH1 adjacent to the human H-CH2-CH3
exons.
The chicken IgHM locus contained much longer introns
(over 4kb between CH1 and CH2) than human or mouse
Ig genes ( 0.1–0.3kb) and composed of large tandem
repeats, including regions possibly related to avian-speciﬁc
CNM and PIR repeats with a 21-bp consensus sequence
(16,17). One of these segments could be digested by the
restriction enzyme BseRI to be replaced by the human
IgHG1 fragment and a ﬂanking selectable marker
cassette (Figure 1A). To verify the construct integration
(Figure 1B), selected stable DT40 transformants were
analyzed by PCR ampliﬁcation of a 4.5-kb fragment
from the beginning of chicken CH1 to the marker gene
(data not shown). We conﬁrmed by RT-PCR and
sequence analysis the mRNA expression of the chimeric
chicken/human IgG1 heavy-chain (ch/hu-IgHG1) which
contained as predicted the VDJ-CH1 region of chicken
IgHM fused to the H-CH2-CH3 region of human IgHG1
(Figure 1B and C). We also detected the simultaneous
expression of the full-length chicken IgHM transcripts,
presumed to be produced by alternative splicing leading
to the removal of the human IgHG1 insert (Figure 1B
and C).
We choose one of the positive chimera transformants,
referred to as the strain CX13, for further analysis of the
expression of chicken IgM and of chimeric IgG (Figure 2).
We ﬁrst conﬁrmed that the chimeric CX13 cells expressed
membrane-bound IgM, which were detectable at levels
comparable to the parental wild-type (WT) cells by
ﬂow-cytometry using a ﬂuorescein-conjugated anti-
chicken IgM antibody (Figure 2A). The presence of
chicken IgM and of chimeric IgG secreted into the
culture medium was also detected by quantitative
sandwich ELISA using anti-chicken IgM and anti-human
IgG antibodies. The concentration of chimeric IgG in
culture supernatants was about 5-fold lower than
chicken IgM (Figure 2B). Nonetheless, the concentration
of chimeric IgG reached between 0.5 and 1.1mg/ml after
1day in cultures containing around 1 10
6 cells (data not
shown, estimation based on ﬁve random independent
cultures), which is comparable to the productivity of re-
combinant antibodies in stable CHO cells under
nonoptimized conditions [0.1–1.1pg/cell/day (18)].
The expression of chimeric ch/hu-IgHG1 in the CX13
culture supernatant was conﬁrmed by western blotting
(Figure 2C, lane 3), but the corresponding band
appeared at a higher position than expected compared
to the control human IgHG1 (lane 1). This difference is
most likely due to the higher glycosylation levels of ch/
hu-IgHG1, as ch/hu-IgHG1 includes the CH1 exon of
chicken IgHM, which contains an asparagine
N-glycosylation consensus site (Asn-Asn-Ser) evolution-
ary conserved in IgHM, but absent from human IgHG1.
After puriﬁcation of chimeric IgG with a protein G
afﬁnity column followed by enzymatic removal of
N-glycans by PNGase F, the band of ch/hu-IgHG1
migrated at the correct predicted size of about 50kDa
(lane 6).
These results demonstrated that DT40 cells stably trans-
formed with the ch/hu-IgHG1 construct generate at the
same time whole secreted-form chimeric IgG, secreted-
form chicken IgM and membrane-bound chicken IgM.
In a same cell, all three Ig variants are presumed to
share the same antigen-binding domain and thus poten-
tially recognize the same antigen. We therefore used the
chimera transformant CX13 to generate a library of
chimeric IgG that could be adapted to the screening of
speciﬁc antibodies with the ADLib system. The overall
strategy used in this method is illustrated in Figure 1D.
Application to the ADLib system for the selection of
chimeric IgG antibodies
To prepare a diversiﬁed library of cells producing chimeric
IgG, we cultured CX13 cells for 6 weeks in the presence of
2.5ng/ml TSA. We conﬁrmed by sequence analysis that
the prolonged treatment with TSA stimulated sequence
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parental sequence of CX13 before expansion, 100% of the
sequence patterns analyzed at the IgL locus and 54% at
the IgH locus showed alterations, the majority of which
could be attributed to gene conversion events (Figure 2D).
The frequency of sequence alterations was comparable to
the frequency usually observed in TSA-treated wild-type
DT40 (5,7). Using primers speciﬁc to ch/hu-IgHG1, we
also conﬁrmed that the transcripts corresponding to the
chimeric IgG also contained diversiﬁed sequence patterns
(data not shown).
Having obtained a display library of cells with
diversiﬁed antibodies on their surface, we applied the
ADLib system to select antigen-speciﬁc clones (5,6),
using apoferritin as target antigen. We screened a reper-
toire of about 10
8 cells from the above-diversiﬁed cul-
ture with apoferritin-conjugated magnetic beads, and
we succeeded in isolating several clones producing
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Figure 1. The chicken/human chimeric IgG expression construct. (A) Strategy for the knock-in of the human IgHG1 constant region at the chicken
IgHM locus. The chicken IgHM region from the exon CH1t oC H3 was cloned to make the targeting vector. The intronic region digested by BseRI
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culture supernatants of these clones contained
secreted-form chicken IgM, which were highly speciﬁc to
apoferritin (Figure 3A). We also observed that the same
samples contained apoferritin-speciﬁc chimeric IgG,
although the ELISA signal intensity was lower than for
chicken IgM (Figure 3A). The lower reactivity might be
due to the 5-fold lower concentration of chimeric human
IgG as compared to chicken IgM (Figure 2B). To test this
idea, we selected a clone with a high IgG to IgM signal
ratio (clone #12 of Figure 3A) and we puriﬁed the IgG
antibodies from a saturated culture supernatant using
protein G columns. The concentration of chimeric IgG
before puriﬁcation as determined by quantitative ELISA
was 0.54mg/ml. We eluted the sample after puriﬁcation in
a buffer volume that allowed an over 10-fold enrichment
of chimeric IgG (ﬁnal concentration 5.61mg/ml).
The ELISA reactivity to apoferritin increased accordingly
as expected (Figure 3B). These results indicate that the
puriﬁed chimeric IgG is highly speciﬁc to the target
antigen but exhibits less reactivity in the initial culture
supernatants due to interference by the excess of coexist-
ing chicken IgM.
We also compared the afﬁnity of chicken IgM and of
chimeric IgG to apoferritin by the method of Rath et al.
(14), which provides a measurement of the relative
antibody afﬁnity by competitive ELISA. By plotting the
percentage of binding as a function of competitor antigen
concentration (Figure 3C), we determined the concentra-
tion of competitor required to inhibit 50% of the binding
of the free antibody in solution (IC50). The IC50 is
correlated to the dissociation constant of the antibody.
The average IC50 values for two independent clones
(clone #3 and #12 of Figure 3A) were very similar
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dilution in PBS. Lanes 1 and 4: human IgG1 positive control. Lane 2: parental WT showing no expression of chimera IgG. Lanes 3, 5 and 7: CX13
coexpressing chimeric IgG and chicken IgM. Lanes 6 and 8: CX13 after deglycosylation with PNGase F. (D) Sequence diversiﬁcation induced in the
Ig variable region after culture expansion for 6 weeks in presence of TSA. The proportion of cells containing sequence alterations compared to the
parental chimera CX13 clone was determined by sequence analysis: GC=gene conversion tracts, PM=point mutations, none=no alteration.
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chimera IgG (1.7nM). These results suggest that the se-
lection of antigen-speciﬁc chicken IgM from the CX13
chimera-derived library allowed the simultaneous
selection of chimeric IgG with the same speciﬁcity and
afﬁnity for the target antigen.
We also noticed that, in some particular cases, the
selected candidates appeared to produce chimeric IgG
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Figure 3. Selection of antigen-speciﬁc chimeric IgG. (A) Primary screen of anti-apoferritin mAbs selected with the ADLib system from the chimera
CX13 derived library. Isolated clones (1–15) were grown for 1 week after selection. Antigen-speciﬁc chicken IgM and chimeric IgG were detected by
ELISA using apoferritin-coated immunoplates incubated with the culture supernatant samples and with respectively anti-chicken IgM and
anti-human IgG secondary antibodies. O.D. values were corrected with the medium background value. The ratio of the O.D. for human IgG
relative to chicken IgM is indicated above the graphs for each selected clone. The clones with the highest ratio (#12, #3) were kept for further
analysis. (B) Reactivity of the chimeric IgG of apoferritin-speciﬁc clone #12 to different antigens before and after puriﬁcation with a protein G
afﬁnity chromatography column. (C) Determination of the relative binding afﬁnities of puriﬁed apoferritin-speciﬁc chimera IgG and chicken IgM.
Culture supernatants were incubated with serial dilutions of apoferritin and then analyzed by competitive ELISA to compare the reactivity of chicken
IgM and of chimeric IgG in the presence of increasing concentrations of competing antigen. By plotting the ELISA O.D. (represented as a percentage
of the maximal O.D. measured in the absence of any competitor antigen) in function of the concentration of antigen, we determined the concen-
tration needed to inhibit the binding of free antibody by 50% (IC50), which is representative of the antibody afﬁnity. The graphs show the average
and standard deviation values from four independent experiments using two different apoferritin-speciﬁc clones (#3 and #12). Calculated IC50 for
chimera IgG=1.7nM; IC50 for chicken IgM=1.8nM. (D) Comparison of two apoferritin-speciﬁc clones (#3 and #14) showing different
antigen-binding reactivity after puriﬁcation of chimeric IgG.
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the corresponding IgM. For instance, the clones #3 and #
14 of Figure 3A showed a similar speciﬁcity of IgM to
apoferritin, whereas the speciﬁcity of chimeric IgG
appeared signiﬁcantly reduced for #14 compared to #3
as shown by the difference in their IgG to IgM speciﬁcity
signal ratio (respectively 0.08 and 0.24). Even after puriﬁ-
cation with protein G columns, the speciﬁcity of chimeric
IgG from clone #14 stayed at a much lower level than the
IgG from clone #3, although the concentrations of IgG
were similar (Figure 3D). This suggests that some clones
such as #14 might not be suited to the conversion of IgM
into chimeric IgG, possibly because structural alterations
affect the conformation of their antigen-binding site. Such
problems are often experienced during the process of gen-
etically engineering conventional monoclonal antibodies
to convert them into human IgG. The present system
can readily eliminate such ‘class-switch sensitive’ clones
at the stage of primary screenings by simply considering
the IgG to IgM signal ratio.
Increase of chimeric IgG secretion by enhancement of
RNA cleavage-polyadenylation
We next wondered if we could shift the IgG to IgM ex-
pression ratio in favor of a higher concentration of IgG in
the culture supernatant, in order to increase the produc-
tion of chimeric IgG. In B cells, the simultaneous expres-
sion of membrane-bound IgM and of secreted-form IgM
is controlled by the balance between competing RNA
cleavage–polyadenylation and RNA splicing reactions
(19): the use of a promoter–proximal poly(A) site leads
to the production of secreted-form IgM, while
exon-skipping by alternative splicing and the use of a
distal poly(A) site lead to the production of
membrane-bound IgM. When B cells differentiate into
mature plasma cells, the use of the promoter–proximal
poly(A) site is enhanced by the overexpression of
polyadenylation and elongation factors such as CstF-64
and ELL2 (20,21), leading to an increased production of
secreted-form IgM over membrane-bound IgM.
We investigated whether the production of chimeric
IgG could be increased in a similar manner by
overexpression of CstF-64, as our construct includes a
poly(A) termination site after the human IgHG1 insert.
We transfected the CX13 chimera cells by random inte-
gration of an expression plasmid with the N-terminal
FLAG-tagged CstF-64 under the CAGGS promoter,
and veriﬁed CstF-64 protein expression by western
blotting using anti-FLAG antibody (Figure 4A).
RT–PCR analysis showed that the transcript level of ch/
hu-IgHG1 was not affected in CstF-64 overexpressing
cells (CstF-64
+ cells) compared to the parental CX13
cells (Figure 4B). In striking contrast, the ch-IgHM tran-
scripts were drastically reduced in CstF-64
+ cells (over
27-fold reduction). This indicates that chicken IgM ex-
pression was severely repressed in CstF-64
+ cells, consist-
ent with the loss of membrane-bound IgM in FACS
analysis (Figure 4C).
We also analyzed the amounts of chimeric IgG secreted
in the culture supernatants by quantitative ELISA
(Figure 4D). To ensure that any differences in the concen-
trations of IgG were not due to variations in cell growth,
we started cultures using two independent clones with
different initial cell densities (from 0.5 10
6 to
2 10
6cells/ml) and we took supernatants after 16h
(shorter than the doubling time in medium without
chicken serum). The concentrations of chimeric IgG in
the CstF-64
+ supernatants were 2–3-fold higher than
those from the parental CX13 cells (Figure 4D). By
contrast, as expected from the transcription analysis, the
concentration of IgM in CstF-64
+ supernatants was
strongly reduced by at least 10-fold (Figure 4E).
Taken together, these experiments demonstrated that
the overexpression of the polyadenylation factor CstF-64
in CX13 cells induced the shutdown of chicken IgM ex-
pression and the relative increase of IgG synthesis, which
resulted in a shift of the ratio of the concentration of IgG
to IgM from 1:5 to about 4:1 and thus in a substantial
improvement of the chimeric IgG production.
DISCUSSION
We described in this report new DT40 strains designed to
express chimeric IgG antibodies containing chicken
antigen-binding regions and human constant regions of
the IgG isoform. The production of chimeric human
IgG would allow easier puriﬁcation and wider application
than IgM, notably for therapeutic uses dependent on Fc
region-mediated functions. By exploiting the alternative
splicing processes speciﬁcally enabled in B cells, our con-
structs allow the coexpression of secreted chimeric IgG
and of membrane-bound chicken IgM in the same cell.
These cells can therefore be used to generate an autono-
mously diversifying library of antibodies displayed at the
cell surface, from which antigen-speciﬁc clones can be
isolated by the direct application of the ADLib system.
This method presents the great advantage of allowing
the selection and production of whole chimeric IgG
mAbs in a single step, without the need of further manipu-
lation such as making recombinant proteins from phage
DNA. Other successful systems of antibody generation by
display on mammalian cells have been reported, but still
require a conversion to secreted-form IgG before
re-expression in productive cells (22,23). Moreover, we
showed that the co-selection of secreted IgG with the
native IgM allows the immediate discrimination of the
mAbs that do not retain their antigenic speciﬁcity after
conversion to IgG. The direct acquisition of IgG would
therefore facilitate the implementation of validation
assays and may bring considerable gain in the time and
effort required for the screening and lead optimization of
new mAb candidates.
We demonstrated that the modulation of splicing/
cleavage–polyadenylation efﬁciency by CstF-64
overexpression induced the cells to switch from the expres-
sion of IgM to an enhanced production of chimeric IgG.
Interestingly, when the overexpression of CstF-64 was ﬁrst
reported by Takagaki et al. (21) to induce a switch of
membrane-bound IgM to secreted-form IgM, the
observed increase of membrane-bound to secreted-form
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whereas in our experiments the IgM expression was much
more reduced, resulting in an increase of the IgG to IgM
ratio by at least 20-fold. This might be explained by the
fact that the cleavage–polyadenylation reaction at the end
of the inserted chimeric IgG would be more efﬁcient than
at the end of IgM, possibly because the IgG cleavage–
polyadenylation site is much closer to the promoter (see
Figure 1b), or because there might be some unknown dif-
ferences between the recognition of splicing and/or
cleavage–polyadenylation signal sites of different Ig
isotypes or different animal species. Thus, the
overexpression of CstF-64, possibly combined with a con-
ditional expression system to prevent the loss of
membrane-bound IgM during the ADLib selection
phase, would ensure a high productivity of chimeric
human IgG while minimizing the expression of chicken
IgM after the selection. This would provide a great prac-
tical advantage to facilitate further characterization of the
selected IgG and their use in various biological assays.
Finally, it should be noted that the same strategy is
presumably applicable to produce chimeras of other
isotypes and other animal species at will. These results
open promising prospects for systems capable to
generate any type of antibodies, including fully humanized
IgG for therapeutic purposes or even mimetic molecules
with various protein scaffolds (24), by inserting the right
expression construct at the appropriate genomic location.
The versatility of the ADLib system applicable to a broad
range of antigens (5,6), in combination with the recent
development of DT40 afﬁnity maturation systems
(11,12) and with the direct generation of chimeric mAbs
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Figure 4. Effects of CstF-64 overexpression on chimera IgG and surface IgM expression. (A) Overexpression of exogenous FLAG-tagged CstF-64
shown by anti-FLAG western blot analysis of 5ml WCE from the parental chimera CX13 and two transfected clones (CstF-64+).
(B) Semiquantitative RT–PCR analysis of the expression of chicken IgM and chimeric IgG. The same primers as in Figure 1 were used to
amplify transcript products from serial dilutions of total RNA starting from a concentration of 50ng/ml. Ampliﬁcations of b-actin transcripts
were used as normalization controls. The average ratios of the transcript levels in CX13 relative to the levels in CstF-64+were estimated by gel band
quantiﬁcation. (C) Flow-cytomeric analysis showing the loss of membrane-bound chicken IgM in CstF-64+cells. Surface IgM-positive and -negative
populations were determined in each culture by the same method as in Figure 1a. While the parental CX13 cells are mostly IgM+ as shown
previously (upper graph), 95% of the CstF-64+ cells appear IgM– (bottom graph). (D) Concentration of chimeric IgG in culture supernatants
determined by quantitative ELISA. Cultures of CX13 and of CstF-64+ cells were started with different initial cell densities as indicated and
supernatant samples were taken after 16h. Each bar shows the average and standard deviation values from two independent experiments performed
each with two different clones cultured in the same conditions. (E) Concentration of chicken IgM in culture supernatants determined by quantitative
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16h. Each bar shows the average and standard deviation values from two different clones cultured in the same conditions.
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provide a fully integrated system to raise high-quality
mAbs against any target of choice in a single step.
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